A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer by Gross, Mitchell et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Cancer
Open Access Research article
A phase II trial of docetaxel and erlotinib as first-line therapy for 
elderly patients with androgen-independent prostate cancer
Mitchell Gross*1, Celestia Higano2, Allan Pantuck3, Olga Castellanos1, 
Erica Green1, Koo Nguyen1 and David B Agus1
Address: 1Louis Warschaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA, 2Department of Medicine, University 
of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA and 3Department of Urology, David Geffen School of Medicine at UCLA, 
Los Angeles, CA, 90095, USA
Email: Mitchell Gross* - mitchell.gross@cshs.org; Celestia Higano - thigano@washington.edu; Allan Pantuck - apantuck@mednet.ucla.edu; 
Olga Castellanos - olga.castellanos@cshs.org; Erica Green - erica.green@cshs.org; Koo Nguyen - koo.nguyen@cshs.org; 
David B Agus - david.agus@cshs.org
* Corresponding author    
Abstract
Background: Docetaxel is the standard first-line agent for the treatment of androgen-independent prostate
cancer (AIPC). The combination of docetaxel with molecularly targeted therapies may offer the potential to
increase the efficacy and decrease the toxicity of cytotoxic chemotherapy for prostate cancer. Previous studies
demonstrate activation of the human epidermal growth factor receptor (EGFR) in prostate cancer. Erlotinib is a
specific inhibitor of the tyrosine-kinase activity of EGFR. The goal of this study is to determine the anti-cancer
activity docetaxel combined with erlotinib for the treatment of elderly subjects with AIPC.
Methods: This is a multi-institutional Phase II study in patients with histologically confirmed adenocarcinoma of
the prostate and age ≥ 65 years. Patients were requred to have progressive disease despite androgen-deprivation
therapy as determined by: (1) measurable lesions on cross-sectional imaging; (2) metastatic disease by
radionucleotide bone imaging; or (3) elevated prostate specific antigen (PSA). Treatment cycles consisted of
docetaxel 60 mg/m2 IV on day 1 and erlotinib 150 mg PO days 1–21. Patients with responding or stable disease
after 9 cycles were eligible to continue on erlotinib alone as maintenance therapy.
Results:  Characteristics of 22 patients enrolled included: median age 73.5 years (range, 65–80); median
Karnofsky Performance Status 90 (range 70–100); median hemoglobin 12.1 g/dl (range, 10.0–14.3); median PSA
218.3 ng/ml (range, 9–5754). A median of 6 treatment cycles were delivered per patient (range 1–17). No
objective responses were observed in 8 patients with measurable lesions (0%, 95% CI 0–31%). Bone scan
improvement and PSA decline was seen in 1 patient (5%, 95% CI 0.1–25%). Five of 22 patients experienced ≥ 50
% decline in PSA (23%, 95% CI 8–45%). Hematologic toxicity included grade 3 neutropenia in 9 patients and
neutropenic fever in 2 patients. Common non-hematologic toxicities (≥ grade 3) included fatigue, anorexia, and
diarrhea.
Conclusion: Docetaxel/erlotinib can be delivered safely in elderly patients with AIPC. Anti-cancer disease
activity appears generally comparable to docetaxel when used as monotherapy. Hematologic and non-
hematologic toxicity may be increased over docetaxel monotherapy. Prospective randomized studies would be
required to determine if the toxicity of docetaxel and erlotinib justifies its use in this setting.
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Background
Prostate cancer is a significant cause of cancer morbidity
and mortality with a projected U.S. incidence of 230,000
cases diagnosed and 27,000 deaths in 2006 [1]. The pro-
gression to androgen-independent prostate cancer (AIPC)
marks a stage of clinical acceleration to a lethal form of the
disease. Mitoxantrone is commonly used for AIPC based
on improvement in pain measures with no effect on over-
all survival [2,3]. Two large Phase III trials recently dem-
onstrated a survival advantage for docetaxel over
mitoxantrone and have led to the widespread use of
docetaxel as first-line treatment for AIPC [4,5].
The human epidermal growth factor receptor (EGFR)
tyrosine kinases are part of a network of pathways which
are implicated in the development and progression of
prostate cancer, in particular as part of the progression to
androgen-independent growth [6-10]. Erlotinib is a selec-
tive inhibitor of the tyrosine kinase activity of the EGFR.
Erlotinib was approved by the US Food and Drug Admin-
istration as a first-line therapy (in combination with gem-
citabine) for pancreatic cancer and as second or third-line
therapy for non-small cell lung cancer (NSCLC) based on
improvement in overall survival [11,12].
The combination of pre-clinical and clinical data linking
the HER-kinase axis to AIPC and early clinical data which
demonstrated the safety of erlotinib in combination with
docetaxel on a three-week schedule led us to perform this
clinical study to examine the efficacy of erlotinib with
docetaxel in AIPC [13].
A significant portion of patients treated with metastatic
AIPC are elderly. The median patient age in the recent
multi-center trials of first-line chemotherapy for AIPC tri-
als was >65 years [4,14]. Older patients may not tolerate
standard or investigational cytotoxic chemotherapies as
well as younger patients [15]. Selection bias may limit
extrapolation of results from non-randomized trials as
patients treated in specialized referral centers may be
younger and with better performance status than the gen-
eral patient population. Therefore, we restricted our inves-
tigation to elderly patients (defined as age ≥ 65 years) to
increase the feasibility and relevance of our results to the
management of AIPC.
Methods
Study design
This study was a multi-center, non-randomized phase II
study. The primary endpoint was best overall response
and response duration for elderly patients with AIPC. Sec-
ondary endpoints were changes in PSA levels, safety, and
changes in patient reported health-related quality of life
measures. At entry, patients were categorized according to
extent and type of metastatic disease (bone, visceral/
lymph nodes, or both) for later response assessment.
Eligibility
Patients were required to have histologically confirmed
adenocarcinoma of the prostate progressed following pri-
mary or secondary hormonal manipulations. Disease pro-
gression was defined as at least two successive increases in
serum PSA (> 20% rise from baseline value) taken at least
two weeks apart or documented soft tissue or osseous pro-
gression demonstrable on imaging studies. Prior hormo-
nal treatment (flutamide, ketoconazole,
diethylstilbesterol) must have been discontinued at least
four weeks prior to study treatment (6 weeks for bicaluta-
mide). Other entry criteria included: age ≥ 65 years;
Karnofsky Performance Status (KPS) ≥ 70%; castrate levels
of testosterone (≤ 50 ng/ml) maintained with medical or
surgical castration; no prior treatment with cytotoxic
chemotherapy; peripheral neuropathy ≤ grade 1; and
appropriate renal, hepatic, and hematologic function con-
sistent with package insert for docetaxel. The Institutional
Review Boards at participating institutions approved this
protocol and all patients were counseled regarding the
benefits, risks, and alternatives to study participation. All
patients signed written informed consent forms before
any study related procedures were performed.
Treatment
Treatment consisted of docetaxel 60 mg/m2 IV over 60
minutes every 21 days and erlotinib 150 mg orally daily
for 21 days. Patients received dexamethasone 8 mg orally
twice daily for 3 days beginning one day prior to the
docetaxel infusion. Anti-emetics were administered as per
institutional standard of care.
A complete blood count, PSA, AST, ALT, alkaline phos-
patase, total bilirubin, BUN, creatinine, and electrolytes
were obtained at baseline and prior to each cycle of ther-
apy. Patients were evaluated with cross sectional imaging
of chest, abdomen, and pelvis and radionucleotide bone
scintigraphy at baseline and after every 3 cycles. An elec-
trocardiogram was obtained at screening.
Patients without objective progression of disease (at least
stable bone scans and/or stable disease by RECIST criteria)
following 9 cycles of docetaxel/erlotinib were allowed to
continue on 3 weeks cycles of erlotinib therapy adminis-
tered alone for up to 8 additional cycles.
Dose modifications
For erlotinib, dose reductions to 100 mg, 50 mg, or 25 mg,
were required for moderate to severe (≥ grade 3) keratitis,
rash, or diarrhea. Dose interruptions of erlotinib for up to
two weeks were allowed as clinically indicated for erlo-
tinib-related toxicities. For docetaxel, a 25% dose reduc-BMC Cancer 2007, 7:142 http://www.biomedcentral.com/1471-2407/7/142
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tion for hematologic toxicities (neutropenia and
thrombocytopenia ≥ grade 3) was allowed. Alternatively,
myeloid growth factor support for secondary prophylaxis
of neutropenia was permitted without dose modification.
Dose interruption followed by a subsequent 25%
docetaxel dose reduction was required for liver enzyme
abnormalities including total bilirubin > upper limit of
normal (ULN), alkaline phosphatase > 5 × ULN, and
alanine transferase >5 × ULN. Dose reductions were also
required for neuropathy ≥ grade 2 and other toxicities ≥
grade 3. Dose delays were required if stomatitis was
present on day 1. If moderate to severe (≥ grade 3) stoma-
titis occurred during any cycle, then subsequent docetaxel
doses were reduced by 25%.
Toxicity and response criteria
The National Cancer Institute Common Toxicity Criteria
(version 2.0) was used to evaluate patient toxicity during
each cycle. Adverse events were reported to authorities as
required by institutional and regulatory guidelines. Every
effort was made to administer the regimen at full dose, as
tolerated. Standard supportive care measures were
employed according to routine local practice.
At entry, patients were classified by disease site according
to the presence of measurable lesions by RECIST criteria
or non-measurable lesions (by bone scan only) [16].
Patients were evaluated after 3 cycles with bone scans and/
or cross sectional imaging as clinically indicated. For
patients with measurable disease, response was assessed
by standardized RECIST criteria [16]. For patients with
bone-only disease, response was assessed by a combina-
tion of an improvement in non-measurable lesions (on
bone scan) and a reduction in PSA levels (≥ 50%) sus-
tained for at least 21 days. Patients with at least stable dis-
ease were continued on therapy. Additional response
evaluations were performed after cycles 6, 9, 13, and at
study completion (following cycle 17 or at early termina-
tion).
Serial measurements of PSA were obtained at baseline and
before every cycle. Criteria for response for declines in PSA
were based on the guidelines from the PSA working group
[17].
Patient reported quality of life outcomes were measured
with the FACT-P questionnaire at baseline (day 1 prior to
study treatment) and before every treatment cycle.
Patients were also asked to complete the FACT-P at the
early termination visit, if applicable.
Statistical considerations
The primary outcome variable was response for each
patient as classified by measurable or non-measurable dis-
ease. Secondary end points included toxicity, patient
reported quality of life, and survival. The study was pow-
ered to both estimate the true percent of responders with
a tolerance of +/- 23%, based on an exact 95% confidence
interval, and to test the null hypothesis of a 5% response
versus >5% response with 90% power with a significance
level of 0.05. Confidence intervals for the proportion
responders were computed using exact binominal confi-
dence intervals. Changes in mean FACT-P scores from
baseline to cycle 3 and baseline to end-of-study visit were
computed with two-sided Student's t-tests. The Kaplan-
Meier curve and mean survival were calculated with S-Plus
(version 5; Insightful).
Results
Patient characteristics
Between November 2002 and July 2005, 22 patients
entered the study at three sites. Patient baseline character-
istics are summarized in Table 1. Patient characteristics
included a median age of 73.5 years (range 65–80 years)
and median performance status of 90 (range 70–100).
Primary therapy included radical prostatectomy alone in
6 patients, radiotherapy alone in 2 patients, primary
androgen-deprivation therapy (ADT) in 7 patients, and
combined prostatectomy and local radiotherapy in 7
patients. The median duration of ADT was 60 months
(range 8–132 months) and most patients progressed after
a median of 2 secondary hormonal agents (range 0–5).
The median pre-treatment PSA was 218 ng/ml. Fourteen
had metastatic disease in bone only, 2 patients had soft
tissue disease only, and 6 patients had both bone and soft
tissue disease.
Table 1: Baseline patient characteristics
Mean (SD) Median (range)
Age (years) 74 (5.1) 74 (65–80)
KPS 87.7 (9.7) 90 (70–100)
Hemoglobin (g/dl) 12.1 (1.3) 12.1 (10.0–14.3)
PSA (ng/ml) 665 (1230) 218.3 (9–5754)
Alkaline phosphatase (U/l) 223 (208) 126.5 (51–768)
Duration of androgen deprivation 
(months)
65.8 (36.3) 60 (8–132)
Secondary hormonal manipulations 2.4 (1.5) 2 (0–5)
Primary Therapy Number
Prostatectomy 13
Prostatectomy and radiation 7
Radiation alone 2
Androgen-deprivation therapy 
alone
7
Sites of Disease
Bone only 14
Visceral only 2
Both 6BMC Cancer 2007, 7:142 http://www.biomedcentral.com/1471-2407/7/142
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Study treatment delivered
A total of 121 cycles of docetaxel with erlotinib were
administered to 22 patients. The median number of treat-
ment cycles delivered per patient was 6 (range 1–17). Dur-
ing combination treatment, there were 10 dose reductions
and 12 dose delays of docetaxel and 3 dose reduction and
3 dose delays of ≥ 7 days of erlotinib due to adverse
events. The average dose intensity of docetaxel was 17.8
mg/m2/week (standard deviation [SD], 3.6). The treat-
ment plan specified erlotinib monotherapy after comple-
tion of 9 cycles of docetaxel/erlotinib combination
treatment with stable disease or better response. Six
patients remained on study after cycle 9 to receive a total
of 23 cycles of erlotinib monotherapy. There were no dose
reductions or delays for erlotinib monotherapy.
Reasons for withdrawal from the study included disease
progression in 8 patients, toxicity in 6 patients, and inves-
tigator discretion in 6 patients. Two patients completed
study drug treatment (after 17 cycles) with stable disease.
Response and overall survival
All patients entered in the trial were evaluable by PSA cri-
teria (Table 2). Of the 22 patients enrolled, 5 had ≥ 50%
decline in PSA (23%, 95% CI 8–45%). None of 8 patients
with measurable disease had objective response by
RECIST criteria and 1 of 20 patients had a clinical
response by composite of bone and PSA criteria (5%, 95%
CI 0.1–25%).
With a median duration of follow-up of 19.0 months, a
median overall survival of 24.6 months was observed
(Figure 1). Five patients remain alive. There were no
deaths during the active treatment phase of the trial, but
14 patients died in follow-up. Three patients were lost to
follow-up.
Toxicity
Common treatment-related toxicities, expressed on a per
patient basis, are summarized in Table 3. Anemia was the
most common hematologic toxicity observed as mild
(grade 1 or 2) in 8 patients and moderate (grade 3 or 4) in
1 patient. Neutropenia was observed as mild (grade 1 or
2) in 3 patients and moderate (grade 3 or 4) 9 patients.
There were two episodes of neutropenic fever. The most
common non-hematologic toxicities were rash (usually
grade 1) in 21 patients and fatigue which was mild (grade
1 or 2) in 17 patients and moderate (grade 3 or 4) in 7
patients. Gastrointenstinal toxicities were also common
including taste alteration, nausea, mucositis, and diarrhea
(all generally grade 1 or 2). Significant (grade 3 or 4) non-
hematologic toxicities (other than fatigue) were rare and
included anorexia (3 patients) and diarrhea (2 patients).
Other common, mild (grade 1 or 2) toxicities included
mucositis, rash, elevated transaminases (AST or ALT), diz-
ziness, hypertension, and ocular irritation.
Patient reported quality of life measures
Patients were asked to complete the FACT-P questionnaire
before treatment at cycle 1 (baseline), cycle 3, and at the
end-of-study visit (occurring variably before cycles 3
through 17). The mean ± SD FACT-P scores observed at
baseline, cycle 3, and end-of-study were112 ± 11 (22
patients); 112 ± 14 (18 patients), 106 ± 17 (20 patients),
respectively. No significant differences were observed in
pair-wise comparisons between mean FACT-P at baseline
and cycle 3 and baseline and end-of-study (p > 0.05).
Discussion
The development of specific inhibitors of the HER-kinase
axis represents an important advance in oncology. In
many pre-clinical models, inhibitors of HER-kinase path-
way are found to be additive or synergistic when com-
bined with cytotoxic agents. This study demonstrates that
docetaxel (60 mg/m2 every 21 days) with erlotinib 150 mg
daily is active and well-tolerated therapy for elderly
patients with AIPC.
This trial was designed and executed before the results of
randomized trials of erlotinib or geftinib (a related EGFR-
tyrosine kinase inhibitor) with cytotoxic chemotherapy
for other solid tumors became available. In non-small cell
lung cancer, four large randomized trials of erlotinib or
geftinib with first-line cytotoxic chemotherapy demon-
strated no additive anticancer effect of the combination
[18-21]. Subsequently, erlotinib was shown to increase
overall survival over supportive care for patients previ-
ously treated with cytotoxic chemotherapy [12]. In pan-
creatic cancer, a recent trial showed a small, but
statistically significant, improvement in overall survival
with erlotinib added to gemcitabine versus gemcitabine
alone in the first-line setting [11]. These data suggest that,
in some settings, EGFR-tyrosine kinase inhibitors may
produce a modest increase in anti-cancer efficacy when
added to cytotoxic chemotherapy. However, additional
data are needed to better understand patient selection and
sequencing for these agents.
The toxicity of docetaxel with erlotinib needs to be consid-
ered in the context of published data for docetaxel and
erlotinib used as monotherapy in comparable patient
Table 2: Best overall response by criteria.
Criteria Response/Evaluable % (95% CI)
PSA 5/22 23 (8–45)
Measurable 0/8 0 (0–31)
Bone disease 1/20 5 (0–25)BMC Cancer 2007, 7:142 http://www.biomedcentral.com/1471-2407/7/142
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populations. Rash and diarrhea are the main dose-limit-
ing toxicities of erlotinib and both were commonly
observe in this trial, though generally mild [22]. Other-
wise, the non-hematologic toxicities of docetaxel with
erlotinib appear comparable to docetaxel montherapy as
reported in the TAX-327 trial [4]. However, the frequency
of dose-modifications and patient withdrawals in this
study raises concerns. In the present study, the median
number of cycles delivered per patient was 6 (of 9 cycles
intended) compared to 9.5 (of 10 cycles intended) in TAX
327 [4]. Further, it is notable that 4 patients withdrew
before the first scheduled evaluation (at cycle 3) due to
toxicity or patient/physician preference. These dose reduc-
tions and delays occurred despite a lower intended dose
intensity of docetaxel at 60 mg/m2 every 21 days com-
pared to 75 mg/m2 every 21 days in TAX-327. These data
may raise concerns regarding the ability to deliver suffi-
cient doses of docetaxel to affect the overall survival
advantage associated with docetaxel-based therapy for
AIPC.
The key results of this trial should also be considered in
the context of the docetaxel monotherapy arm in TAX-327
[4]. We observed a PSA decline of ≥ 50% in 23% (95% CI
8–45%) which just overlaps with the PSA decline rate of
45% (95% CI 40–51%) observed in TAX-327. The
absence of objective responses in 8 patients with measur-
able disease (0%, 95% CI: 0–31%) in our trial is not sur-
prising considering an objective response rate of 12%
(95% CI 7–19%) in TAX-327. Perhaps most significantly,
the median overall survival of 24.6 months compares
favorably with a median survival of 18.9 months observed
in TAX-327 despite a generally older patient population
(mean age 74 years in this report versus 68 years in TAX-
327) and decreased intended dose intensity of docetaxel
(20 mg/m2/week in this report versus 25 mg/m2/week in
TAX-327).
Conclusion
In summary, we found docetaxel with erlotinib to be a rel-
atively well-tolerated regimen in this elderly patient pop-
ulation. Our data suggests that the overall survival of
patients treated with docetaxel and erlotinib appears com-
parable docetaxel monotherapy despite an apparent
increase in toxicity. A randomized study would be needed
to determine if the toxicity of the docetaxel and erlotinib
results in a demonstrable benefit in terms of overall sur-
vival.
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Table 3: Treatment Related Toxicity
Grade 1/2 Grade 3/4
Toxicity No. % No. %
Hematologic
Neutropenia 3 14 9 41
Anemia 8 36 1 5
Febrile neutropenia 0 0 2 9
Leukopenia 3 14 4 18
Lymphopenia 4 18 4 18
Non-hematologic
Fatigue 21 95 1 5
Anorexia 17 77 7 32
Diarrhea 16 72 2 9
Mucositis 14 64 0 0
Rash 13 59 0 0
Liver enzyme elevation (AST) 12 55 0 0
Liver enzyme elevation (ALT) 9 41 0 0
Dizziness 9 41 0 0
Hypertension 7 32 0 0
Ocular irritation 7 32 0 0
Estimate of overall survival Figure 1
Estimate of overall survival. Kaplan-Meier graph showing 
proportion surviving over time (solid line) with estimates of 
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